Gilead Sciences, Inc. (NASDAQ:GILD) Shares Acquired by Fortem Financial Group LLC

Fortem Financial Group LLC increased its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 6.5% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 6,670 shares of the biopharmaceutical company’s stock after acquiring an additional 407 shares during the quarter. Fortem Financial Group LLC’s holdings in Gilead Sciences were worth $616,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. nVerses Capital LLC acquired a new position in shares of Gilead Sciences during the 3rd quarter worth about $25,000. Valued Wealth Advisors LLC raised its holdings in shares of Gilead Sciences by 101.9% during the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 161 shares during the last quarter. Cedar Wealth Management LLC lifted its position in shares of Gilead Sciences by 51.6% in the second quarter. Cedar Wealth Management LLC now owns 470 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 160 shares in the last quarter. Strategic Investment Solutions Inc. IL acquired a new stake in shares of Gilead Sciences in the second quarter worth approximately $33,000. Finally, Quarry LP acquired a new stake in shares of Gilead Sciences in the second quarter worth approximately $43,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

GILD has been the topic of a number of research reports. Leerink Partnrs upgraded Gilead Sciences from a “hold” rating to a “strong-buy” rating in a report on Monday, October 21st. Sanford C. Bernstein started coverage on shares of Gilead Sciences in a research note on Thursday, October 17th. They issued an “outperform” rating and a $105.00 price target on the stock. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $84.00 price objective on shares of Gilead Sciences in a research note on Wednesday, December 11th. Barclays raised their target price on shares of Gilead Sciences from $84.00 to $95.00 and gave the stock an “equal weight” rating in a research note on Thursday, November 7th. Finally, Robert W. Baird upped their price target on Gilead Sciences from $80.00 to $95.00 and gave the company a “neutral” rating in a research report on Thursday, November 7th. Twelve research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and four have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $96.43.

Gilead Sciences Trading Down 0.4 %

Shares of GILD stock traded down $0.35 on Monday, hitting $91.06. The stock had a trading volume of 4,103,792 shares, compared to its average volume of 3,856,787. The company’s 50 day moving average price is $91.81 and its 200-day moving average price is $82.68. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $98.90. The firm has a market capitalization of $113.48 billion, a P/E ratio of 1,011.78, a P/E/G ratio of 2.24 and a beta of 0.18. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.58 by $0.44. The business had revenue of $7.55 billion for the quarter, compared to analysts’ expectations of $7.01 billion. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The business’s quarterly revenue was up 7.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.29 earnings per share. Analysts anticipate that Gilead Sciences, Inc. will post 4.36 earnings per share for the current year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, December 30th. Stockholders of record on Friday, December 13th were given a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a dividend yield of 3.38%. The ex-dividend date of this dividend was Friday, December 13th. Gilead Sciences’s dividend payout ratio is currently 3,422.22%.

Insider Activity

In other news, CFO Andrew D. Dickinson sold 248,645 shares of the firm’s stock in a transaction on Friday, November 29th. The shares were sold at an average price of $92.76, for a total value of $23,064,310.20. Following the sale, the chief financial officer now directly owns 138,919 shares in the company, valued at approximately $12,886,126.44. This trade represents a 64.16 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Jeffrey Bluestone sold 6,788 shares of Gilead Sciences stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total transaction of $620,355.32. Following the sale, the director now directly owns 8,920 shares of the company’s stock, valued at approximately $815,198.80. This trade represents a 43.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 453,734 shares of company stock worth $41,902,086. Corporate insiders own 0.16% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.